Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiken Biomedical CoTPE:7780 -0.60%23 EV-to-EBITDA is 14.89 as of Aug. 18, 2026, which is 47% below its 10-year median of 28.04. GuruFocus rates TPE:7780 with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 1,646 Consumer Packaged Goods companies, Daiken Biomedical Co ranks worse than 78.61% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Daiken Biomedical Co's enterprise value is NT$8,310 Mil.
Daiken Biomedical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was NT$558 Mil. Therefore, Daiken Biomedical Co's EV-to-EBITDA for today is 14.89.
The historical rank and industry rank for Daiken Biomedical Co's EV-to-EBITDA or its related term are showing as below:
TPE:7780'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 14.31 Med: 28.04 Max: 67.53
Current: 14.9
During the past 4 years, the highest EV-to-EBITDA of Daiken Biomedical Co was 67.53. The lowest was 14.31. And the median was 28.04.
TPE:7780's EV-to-EBITDA is ranked worse than 78.61% of 1646
companies
in the Consumer Packaged Goods industry
Industry Median: 9.065
vs TPE:7780: 14.90
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Daiken Biomedical Co (TPE:7780) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Daiken Biomedical Co's PE Ratio (TTM) for today is calculated as:
Daiken Biomedical Co's share price for today is NT$16.70.
Daiken Biomedical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.550.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Daiken Biomedical Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, Daiken Biomedical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiken Biomedical Co EV-to-EBITDA vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Daiken Biomedical Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Daiken Biomedical Co's EV-to-EBITDA falls into.
Daiken Biomedical Co's current Enterprise Value is NT$8,310 Mil.
Daiken Biomedical Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$558 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Daiken Biomedical Co (TPE:7780) has a EV-to-EBITDA of 14.89 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Daiken Biomedical Co. This is 47% below median its historical median of 28.04. Over the past decade, Daiken Biomedical Co's EV-to-EBITDA has ranged from 14.31 to 67.53. According to the industry distribution chart, Daiken Biomedical Co ranks #1294 out of 1646 companies in the Consumer Packaged Goods industry, placing it in the top 78.6%.
Is Daiken Biomedical Co's EV-to-EBITDA too high?
Daiken Biomedical Co's current EV-to-EBITDA of 14.89 is 47% below median its 10-year median of 28.04. Over the past 10 years, this metric has ranged from a low of 14.31 to a high of 67.53. The Consumer Packaged Goods industry median EV-to-EBITDA is 9.07. Daiken Biomedical Co's value of 14.89 is 64.3% above this industry median. Based on the distribution chart, Daiken Biomedical Co ranks #1294 out of 1646 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, Daiken Biomedical Co has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Daiken Biomedical Co's EV-to-EBITDA compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Daiken Biomedical Co ranks #1294 out of 1646 companies for EV-to-EBITDA. This places Daiken Biomedical Co in the lower half of its industry. The industry median EV-to-EBITDA is 9.07. Daiken Biomedical Co's value of 14.89 is 64.3% above this benchmark. Historically, Daiken Biomedical Co's own EV-to-EBITDA has ranged from 14.31 to 67.53 over the past decade. While the company's 10-year median is 28.04 vs. the industry median of 9.07, Daiken Biomedical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Consumer Packaged Goods company?
The median EV-to-EBITDA among Consumer Packaged Goods companies is 9.07, based on 1,646 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiken Biomedical Co's current EV-to-EBITDA of 14.89 is 64.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Daiken Biomedical Co. For the Consumer Packaged Goods industry, the median EV-to-EBITDA is 9.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiken Biomedical Co's current EV-to-EBITDA is 14.89, which is 47% below median its own 10-year median of 28.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiken Biomedical Co stock overvalued right now?
Daiken Biomedical Co (TPE:7780) has a current EV-to-EBITDA of 14.89. The current EV-to-EBITDA is 14.89, which is 47% below median its 10-year median of 28.04 and 64.3% above the Consumer Packaged Goods industry median of 9.07. Daiken Biomedical Co's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Daiken Biomedical Co (TPE:7780), the current EV-to-EBITDA is 14.89 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Daiken Biomedical Co Ltd is engaged in Research, development, and sales of health food. Its products include fish oil capsules, collagen powder, collagen drinks, natto capsules, and mint leaf capsules. The companies reportable operating segment consists solely of the e-commerce division.
23GF Score
Get the complete analysis for TPE:7780
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:7780 has been successfully added to your 
